Management of type 2 diabetes: A handbook for general practice

Lifestyle interventions for management of type 2 diabetes


Download chapter

Last revised: 17 Sep 2020

Grade: A, level 1A

In people with overweight or obesity with diabetes, a nutritionally balanced, calorie-reduced diet should be followed to achieve and maintain a lower, healthier body weight

Grade: A, level 1A

An intensive healthy behaviour intervention program, combining dietary modification and increased physical activity, may be used to achieve weight loss, improve glycaemic control and reduce CVD risk

Grade: A, level 1A

Weight management medication may be considered in people with diabetes and overweight or obesity to promote weight loss and improved glycaemic control

Grade: Consensus

Metabolic surgery should be recommended to manage type 2 diabetes:

  • in people with a body mass index (BMI) ≥40 kg/m2
  • in people with a BMI 35.0–39.9 kg/m2 when hyperglycaemia is inadequately controlled by lifestyle and optimal medical therapy

Grade: Consensus

Metabolic surgery should also be considered for patients with type 2 diabetes and BMI 30.0–34.9 kg/m2 if hyperglycaemia is inadequately controlled despite optimal treatment with either oral or injectable medications

These recommendations are drawn from the most recent recommendations from organisations including the National Health and Medical Research Council (NHMRC), the Scottish Intercollegiate Guidelines Network (SIGN), Diabetes Canada, the American Diabetes Association (ADA) and other relevant sources. Refer to ‘Explanation and source of recommendations’ for explanations of the levels and grades of evidence.

For people with type 2 diabetes who are overweight or obese, even modest weight loss (5–10%) may provide clinical benefits, including improved glycaemic control, blood pressure and lipid profiles, especially early in the disease process.20–22 Lifestyle-induced sustained weight loss contributes to the prevention, or delays progression, of diabetes.23–25

The relationship between weight loss and clinical benefits is complex, however. The multi-centre, randomised clinical trial Action for Health in Diabetes (Look AHEAD) provided evidence that intensive lifestyle intervention focusing on weight loss did not result in a significant reduction in cardiovascular eventsCl in overweight or obese adults with established type 2 diabetes.26 This was despite greater reductions in HbA1c and greater initial improvement in fitness and all CVD risk factors, except for low-density lipoprotein cholesterol levels. Increasing physical activity, regardless of weight loss, may reduce CVD risk factors,27 and reduce HbA1c by ~0.6% in adults with type 2 diabetes.28

The causes of overweight and obesity are likewise complex. Diet and physical activity are central to the energy balance equation, but are directly and indirectly influenced by a wide range of social, environmental, behavioural, genetic and physiological factors, the relationships between which are not yet fully understood. Older people with diabetes may also be at risk of malnutrition.

When managing patients, be mindful that some medications are associated with weight gain, including29 insulin, sulfonylureas, thiazolidinediones, second-generation antipsychotics (especially olanzapine and clozapine), beta-adrenergic blockers (especially propranolol), tricyclic antidepressants, lithium, pizotifen, sodium valproate and glucocorticosteroids.

Practice Point: The concept of diabetes remission

Diabetes ‘remission’ or even ‘reversal’ is often stated as one of the measured outcomes of clinical trials of weight loss interventions, usually defined as reduction or cessation of the use of glucose-lowering agents by participants.

However, the period that normalisation of glycaemia is sustained for varies in the long term, according to study length, intervention methods and time to follow-up. Thus, there is not high-quality evidence to support the concept of ‘reversal’ of diabetes from current interventions.

It is important to encourage a degree of healthy weight loss in anyone with type 2 diabetes who is overweight, except where there are other associated risks (eg in the frail and elderly, or those with eating disorders). Because a healthy body weight is sometimes not achievable, setting this as a goal might discourage patients from attempting any dietary change.

The Australian Obesity Management Algorithm is a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia.

Weight assessment

Assessing weight is typically done using BMI, which can be a difficult parameter to standardise between different population groups.

For those of European descent, a healthy BMI is 18.5–24.9 kg/m2, overweight is 25–29.9 kg/m2 and obese is ≥30 kg/m2.6 Different classification criteria may apply to other population groups. Some groups may have equivalent levels of risk of health problems at a lower BMI (eg these BMI thresholds should be reduced by 2.5 kg/m2 for patients of Asian ethnicity7) or higher BMI (eg Torres Strait Islander and Maori peoples).30

It is advisable to also assess waist circumference (in centimetres), as this is a good indicator of total body fat and a useful predictor of visceral fat. Waist circumference of ≥94 cm in men and ≥80 cm in women conveys increased risk of obesity-related complications; ≥102 cm in men and ≥88 cm in women convey high risk.31 As with BMI, these values may differ for other population groups.6

Measuring waist circumference in patients with a BMI >35 kg/m2 may not add any further to predictive disease risk classification.32

Lifestyle interventions for weight management

In overweight or obese people with diabetes, a nutritionally balanced, energy-reduced diet should be recommended if a lower, healthier body weight is to be achieved and maintained as part of a multi-component lifestyle intervention (including healthy eating, physical activity and support for behavioural change).

Very low energy diets (VLEDs) can be considered as an initial weight loss strategy, when supervised lifestyle interventions have been unsuccessful in reducing weight, or when rapid weight loss is required (eg prior to bariatric or general surgery that is conditional on weight loss).33 These diets may be considered in adults with diabetes with BMI >27 kg/m2, taking into account each individual situation.34 A primary care–based weight loss study, the Diabetes Remission Clinical Trial (DiRECT), showed that VLED with associated weight loss led to 46% of participants reducing or ceasing diabetes medications after 12 months of intervention.35

VLEDs require regular appointments with appropriate health professionals to support the progress of the individual. Caution should be exercised if hypoglycaemia is a risk (people taking sulfonylureas and insulin). Use of sodium glucose co-transporter 2 (SGLT2) inhibitors in people on VLEDs or any high-protein, low-carbohydrate diet is not recommended (due to raised risk of ketoacidosis, which might be euglycaemic).


Pharmacotherapy is licensed by the Therapeutic Goods Administration (TGA) for weight management, including for patients with diabetes, but is not currently reimbursed by the Pharmaceutical Benefits Scheme (PBS). There are now four drugs that can be used as adjuncts to dietary changes and physical activity improvement: phentermine (a sympathomimetic amine), orlistat (an inhibitor of intestinal lipase), liraglutide (a glucagon-like peptide-1 receptor agonist [GLP-1 RA]) and combined naltrexone and bupropion.

These drugs may be considered in adults with diabetes with BMI ≥27 kg/m2, taking into account each individual situation.33

Each drug has the potential for significant clinical side effects and contraindications associated with its use. They require careful clinical risk–benefit assessment when applied in practice. Refer to the TGA website for more information.

Surgical interventions

Surgery for weight loss, also called metabolic or bariatric surgery, may induce weight loss in people who have failed by other means. The following procedures are used in Australia.7,34

  • Sleeve gastrectomy involves removing the greater portion of the fundus and body of the stomach, reducing its volume from up to 2.5 L to about 200 mL. This procedure provides fixed restriction and does not require adjustment like laparoscopic adjustable gastric banding (LAGB).
  • Roux-en-Y gastric bypass is a combination procedure in which a small stomach pouch is created to restrict food intake and the lower stomach, duodenum and first portion of the jejunum are bypassed to produce modest malabsorption of nutrients and thereby reduce kilojoule intake.
  • Biliopancreatic diversion is also a combination procedure that involves removing the lower part of the stomach and bypassing the duodenum and jejunum to produce significant malabsorption. This procedure tends to be performed in subspecialty centres.

Used in the past, LAGB is less used now in Australia and North America due to less sustained weight loss, fewer metabolic benefits and high surgical complication rates. This procedure involves placing a band around the stomach near its upper end to create a small pouch.6

Sleeve gastrectomy, Roux-en-Y gastric bypass and biliopancreatic diversion lead to sustained weight loss and normalisation (refer to ‘Practice Point’ above) of type 2 diabetes metabolic markers, although techniques vary in efficacy.6

The improvement in diabetes metabolic markers for Roux-en Y gastric bypass surgery at two-year follow-up was 52.7% in one meta-analysis, compared with 0.7% for medical management.36 For individuals who achieve improvement in diabetes metabolic markers with Roux-en-Y gastric bypass, the median period of sustained improvement is 8.3 years.7

Metabolic surgery in patients with type 2 diabetes is associated in non-randomised studies with reduction in microvascular and macrovascular complications as well as reduced mortality.7 Moreover, studies have also shown that metabolic surgery can prevent or delay the onset of type 2 diabetes in people with obesity.7

Taking into account each individual situation, metabolic surgery may be considered for people with a BMI >30 kg/m2 who have suboptimal BGLs, are at increased CVD risk and are not achieving recommended targets with medical therapy.7

GPs should assess the appropriateness of metabolic surgery for each individual patient and provide information on the risks, benefits and appropriateness of the type of procedure. Metabolic surgery performed in a high-volume specialist centre with an experienced surgical team may offer the lowest risks, and GPs should liaise with a specialised surgical team if there are concerns.33,34

Metabolic surgery, when indicated, should be included as part of an overall clinical pathway for adult weight management that is delivered by a multidisciplinary team (including surgeons, APDs, nurses, psychologists and physicians), and includes planning for surgery and continuing follow-up.33

Adverse events of metabolic surgery, particularly in the long term, need more research;37 however, suggested follow-up care includes monitoring for nutritional deficiencies and acid reflux disorders.38

Women of reproductive age who have had metabolic surgery need particular advice on contraceptive choices; those who plan to have a pregnancy need assessment, before and throughout pregnancy, regarding nutritional status, need for higher multivitamin dosages and close obstetric monitoring. Referral prior to pregnancy to appropriate specialty services is strongly advised, even if the diabetes appears well managed.

This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log